Long-acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease

References

• Barnes P. Chronic obstructive pulmonary disease. N. Engl. J. Med.343, 269–280 (2000).
   PubMed Web of Science ®Google Scholar
• Rabe K, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.176, 532–555 (2007).
   PubMed Web of Science ®Google Scholar
• Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet370, 760–773 (2007).
   Google Scholar
• Donalson GC, Wedzicha JA. COPD exacerbations 1: epidemiology. Thorax61, 164–168 (2006).
   PubMed Web of Science ®Google Scholar
• Sapey E, Stockley RA. COPD exacerbations 2: aetiology. Thorax61, 250–258 (2006).
   PubMed Web of Science ®Google Scholar
• Mui T, Man P, Sin D. Developments in drugs for the treatment of chronic pulmonary disease. Expert Rev. Clin. Immunol.4, 365–377 (2008).
   PubMed Web of Science ®Google Scholar
• Murray C, Lopez A. Alternative projections of mortality and disability by cause 1990–2020. Global Burden of Disease study. Lancet349, 1498–1504 (1997).
   PubMed Web of Science ®Google Scholar
• Calverley P. COPD: what is the unmet need? Br. J. Pharmacol.155, 487–493 (2008).
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Immunol. Rev.8, 183–192 (2008).
   PubMed Web of Science ®Google Scholar
• Gandevia B. Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders. Postgrad. Med. J.51(Suppl. 7), 13–20 (1975).
   PubMedGoogle Scholar
• Chapman K. History of anticholinergic treatment in airways disease. In: Anticholinergic Therapy in Obstructive Airways Disease. Gross NJ (Ed.). Franklin Scientific Publications, London, UK, 9–17 (1993).
   Google Scholar
• Gross N. Ipratropium bromide. N. Eng. J. Med.319 (8), 486–494 (1988).
   PubMed Web of Science ®Google Scholar
• Herxheimer H. Atropine cigarettes in asthma and emphysema.Br. Med. J.2, 167–171 (1959).
   PubMed Web of Science ®Google Scholar
• Gross JN. Anticholinergic agents in asthma and COPD. Eur. J. Pharm.533, 36–39 (2006).
   PubMed Web of Science ®Google Scholar
• Barnes P. Tiotropium bromide. Drugs62, 1195–1203 (2002).
   PubMed Web of Science ®Google Scholar
• Lu S, Parekh DD, Kuznetsova O, Green SA, Tozzi CA, Reiss TF. An oral selective M3 cholinergic receptor antagonist in COPD. Eur. Respir. J.28, 772–780 (2006).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur. Respir. J.34, 1–13 (2009).
   PubMed Web of Science ®Google Scholar
• Provins L, Christophe B, Danhaive P et al. Dual M3 antagonists -PDE4 inhibitors. Part 2. Synthesis and SAR of 3-substituted azetidinyl derivatives. Bioorg. Med. Chem. Lett.17(11), 3077–3080 (2007).
   PubMed Web of Science ®Google Scholar
• Provins L, Christophe B, Danhaive P et al. First dual M3 antagonists -PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives. Bioorg. Med. Chem. Lett.16(7), 1834–1839 (2006).
   PubMed Web of Science ®Google Scholar
• Norman P. Pfizer’s dual-acting β2-agonists/muscarinic M3 antagonists. Expert Opin. Ther. Patents18(9), 1091–1096 (2008).
   Web of Science ®Google Scholar
• Ray NC, Alcaraz L. Muscarinic antagonist-β-adrenergic agonist dual pharmacology molecules as bronchodilators: a patent review.Expert Opin. Ther. Patents19(1), 1–12 (2009).
   PubMed Web of Science ®Google Scholar
• Caulfield MP, Birdsall NJ. International union of pharmacology. XVII. classification of muscarinic acetylcholine receptors. Pharmacol. Rev.50, 279–290 (1998).
   PubMed Web of Science ®Google Scholar
• Eglen RM. Muscarinic receptor subtype pharmacology and physiology. Prog. Med. Chem.43, 105–136 (2005).
   PubMedGoogle Scholar
• Caulfield MP. Muscarinic receptors-characterization, coupling and function. Pharmacol. Ther.58, 319–359 (1993).
   PubMed Web of Science ®Google Scholar
• Lee AM, Jacoby DB, Fryer AD. Selective muscarinic receptor antagonists for airway diseases. Cur. Opin. Pharmacol.1, 223–229 (2001).
   PubMedGoogle Scholar
• Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc.2, 297–304 (2005).
   PubMedGoogle Scholar
• Gwilt CR, Donnelly LE, Rogers DF. The non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary inflammation. Pharmacol. Ther.115, 208–222 (2007).
   PubMed Web of Science ®Google Scholar
• Barnes PJ. New muscarinic receptor subtypes: implications for lung disease. Thorax44, 161–167 (1989).
   PubMed Web of Science ®Google Scholar
• Gater PJ, Alabastar VJ, Piper I. A study of the muscarinic receptor subtype mediating secretion in the cat trachea in vitro. Pul. Pharmacol.2, 87–92 (1989).
   PubMedGoogle Scholar
• Faulkner D, Fryer AD, MacLagan J. Postganglionic muscarinic inhibitory receptors in pulmonary parasympathetic nerves in the guinea-ig. Br. J. Pharmacol.88, 181–187 (1986).
   PubMed Web of Science ®Google Scholar
• Lammers JJ, Minette, P, McCusker M, Barnes PJ. The role of pirenzepine-sensitive (M1) muscarinic receptors in vagally mediated bronchoconstriction in humans. Am. Rev. Respir. Dis.139, 446–449 (1989).
   PubMed Web of Science ®Google Scholar
• Jartti T. Asthma, asthma medication and autonomic nervous system dysfunction.Clin. Physiol.21(2), 260–269 (2001).
   PubMedGoogle Scholar
• Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir. Research7(1), 73–87 (2006).
   PubMed Web of Science ®Google Scholar
• Fryer AD, Adamko DJ, Yost BL, Jacoby DB. Effects of inflammatory cells on neuronal m2 muscarinic receptor function in the lung. Life Sci.64, 449–455 (1999).
   PubMed Web of Science ®Google Scholar
• Bos IST, Gosens R, Zuidhot AB et al. Inhibition of allergen-induced airway remodeling by tiotropium and budesonide: a comparison. Eur. Respir. J.30, 653–661 (2007).
   PubMed Web of Science ®Google Scholar
• Wess J, Eglen RM, Gautman D. Muscarinic acetycholine receptors: mutant mice provide new insights for drug development. Nat. Rev. Drug Discov.6(9), 721–733 (2007).
   PubMed Web of Science ®Google Scholar
• Gosens R, Bos ST, Zaagsma J, Meurs H. Progressive effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am. J. Respir. Crit. Care Med.171, 1096–1102 (2005).
   PubMed Web of Science ®Google Scholar
• Profita M, Di Giorgio R, Sala A et al. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy60, 1361–1369 (2005).
   PubMed Web of Science ®Google Scholar
• Gosens R, Rieks D, Meurs H et al. Muscarinic M3 receptor stimulation increases cigarette smoke-induced IL-8 secretion by human airway smooth muscle cells. Eur. Respir. J.34(6), 1436–1443 (2009).
   PubMed Web of Science ®Google Scholar
• Matthiesen S, Bahulayan A, Kempkens S et al. Muscarinic receptors mediate stimulation of human lung fibroblast proliferation. Am. J. Respir. Cell. Mol. Biol.35, 621–627 (2006).
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Eng. J. Med.359(15), 1543–1554 (2008).
   PubMed Web of Science ®Google Scholar
• Trevethick M, Clarke N, Strawbridge M, Yeadon M. Inhaled muscarinic antagonists for COPD-does an anti-inflammatory mechanism really play a role? Curr. Opin. Pharmacol.9, 250–255 (2009).
   PubMed Web of Science ®Google Scholar
• Perng DW, Tao CW, Su KC, Tsai CC, Liu LY, Lee YC. Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiototropium in COPD. Eur. Respir. J.33, 778–784 (2009).
   PubMed Web of Science ®Google Scholar
• Disse B, Reichl R, Speck G, Traunecker W, Rominger KL, Hammer R. BA679BR, a novel long-acting anticholinergic bronchodilator. Life Sci.52, 537–544 (1993).
   PubMed Web of Science ®Google Scholar
• Takahashi T, Belvisi MG, Patel H et al. Effect of Ba679BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am. J. Respir. Crit. Care Med.150, 164–1645 (1994).
   Google Scholar
• Hansel T, Barnes P. Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Today38(9), 585–600 (2002).
   PubMed Web of Science ®Google Scholar
• Barnes P. Tiotropium bromide. Exp. Opin. Invest. Drugs10(4), 733–740 (2001).
   PubMed Web of Science ®Google Scholar
• ZuWallack A, ZuWallack R. Tiotropium bromide, a new once-daily inhaled anticholinergic bronchodilator for chronic obstructive pulmonary disease. Exp. Opin. Pharmacother.5(8), 1827–1835 (2004).
   PubMed Web of Science ®Google Scholar
• Lipson D. Tiotropium bromide. Int. J. COPD1(2), 107–114 (2006).
   Google Scholar
• Leusch A, Eichhorn B, Muller G, Romiger K. Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog. Drug. Dispos.22, 199–212 (2001).
   Google Scholar
• Prat M, Fernandez D, Buil AM et al. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration. identification of (3R)-3-{[hydroxyl(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide). J. Med. Chem.52, 5076–5092 (2009).
   PubMed Web of Science ®Google Scholar
• Cazzola M. Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatement od COPD. Curr. Opin. Inves. Drugs10(5), 482–490 (2009).
   PubMed Web of Science ®Google Scholar
• Lock R, Collingwood S, Ratcliffe A. Emerging therapies for respiratory diseases. Drug News Perspect.20 (9), 593–600 (2007).
   PubMedGoogle Scholar
• Gavalda A, Miralpeix M, Ramos I et al. Aclidinium bromide, a novel muscarinic receptor antagonist combining long residence at the M3 receptor and rapid plasma clearance. Presented at: Annual Congress European Respiratory Society. Stockholm, Sweden, 15–19 September 2007 (Abstract 1296).
   Google Scholar
• Miralpeix M, Gavalda A, Morcillo E et al. Assessment of the potency and duration of action of aclidinium bromide in guinea pig isolated trachea in vitro. Presented at: Annual Congress European Respiratory Society. Stockholm, Sweden, 15–19 September 2007 (Abstract P2159).
   Google Scholar
• Miralpeix M, Carreno C, Otal R et al. The inhaled anticholinergic agent, aclidinium bromide, reverses cholinergic-induced bronchoconstriction in guinea pigs with a fast onset of action and a long duration of effect. Presented at: Annual Congress European Respiratory Society. Berlin, Germany, 4–8 October, 2008 (Abstract 3642).
   Google Scholar
• Casarosa P, Bouysson T, Germeyer S et al. Preclinical evaluation of long-acting muscarinic antagonists (LAMAs): comparison of tiotropium and investigational drugs. JPET330(2), 660–668 (2009).
   PubMed Web of Science ®Google Scholar
• Gavalda A, Snetella S, Alberti J et al. Rapid plasma hydrolysis of aclidinium bromide, a novel long-acting anticholinergic drug. Presented at: Annual Congress European Respiratory Society. Berlin, Germany, 4–8 October 2008 (Abstract P3641).
   Google Scholar
• Joos G, Schelfhout V, Kanniess F, Ludwig-Sengpiel A, Gil G, Massana Montejo E. Bronchodilator effects of aclidinium bromide, a novel long-acting anticholinergic, in COPD patients: a Phase II study. Presented at: Annual Congress European Respiratory Scoiety. Stockholm, Sweden, 15–19 September 2007 (Abstract 1299).
   Google Scholar
• Chanez P, Burge S, Dahl R, Creemers J, Lamarca R, Garcia Gil E. Once-daily administration of aclidinium bromide, a novel, long-acting anticholinergic: a Phase II, dose-finding study. Presented at: Annual Congress European Respiratory Society. Berlin, Germany, 4–8 October, 2008 (Abstract 2736).
   Google Scholar
• Franko B, Lunsford C. Derivatives of 3-pyrrolidinaols-III. The chemistry, pharmacology, and toxicology of some N-substituted-3-pyrrolidyl α-substituted phenylacetates. J. Med. Pharm. Chem.2, 523–540 (1960).
   PubMedGoogle Scholar
• Franko B, Alphin R, Ward J, Lunsford C. Pharmacodynamic evaluation of glycopyrrolate in animals. Ann. NY Acad. Sci.99, 131–149 (1962).
   PubMed Web of Science ®Google Scholar
• Barman M, Larson R. The effect of glycopyrrolate on nocturnal gastric secretion in peptic ulcer patients. Am. J. Med. Sci.246, 325–328 (1963).
   PubMed Web of Science ®Google Scholar
• Mirakhur R, Dundee J. Glycopyrrolate: pharmacology and clinical use. Anaesthesia.38, 1195–1204 (1983).
   PubMed Web of Science ®Google Scholar
• Walker F 4th, Kaiser D, Kowal M, Suratt P. Prolonged effect of inhaled glycopyrrolate in asthma. Chest91, 49–51 (1987).
   PubMed Web of Science ®Google Scholar
• Schroeckenstein D, Bush R, Chervinsky P, Busse W. Twelve-hour bronchodilation in asthma with a single aerosol dose of the anticholinergic compound glycopyrrolate. J. Allergy Clin. Immunol.82, 115–119 (1988).
   PubMed Web of Science ®Google Scholar
• Tzelepis G, Komanapolli, Tyler D, Vega D, Fulambarker A. Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease. Eur. Respir. J.9, 100–103 (1996).
   PubMed Web of Science ®Google Scholar
• Hansel T, Neighbour H, Erin EM et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilation in patients with asthma.Chest128, 1974–1979 (2005).
   PubMed Web of Science ®Google Scholar
• Villetti G, Bergamaschi M, Bassani F et al. Pharmaocolical assessement of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea pig and human airways. Br. J. Pharmacol.148, 291–298 (2006).
   PubMed Web of Science ®Google Scholar
• Overend T, Fukuchi Y, Flemale A et al. Dose-ranging study to assess the efficacy and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in patients with COPD. Presented at: Annual Congress European Respiratory Society. Berlin, Germany, 4–8 October 2008 (Abstract P3606).
   Google Scholar
• Laine DI, Wan Z, Yan H et al. Design, synthesis and SAR of tropane muscarinic acetylcholine receptor antagonists. J. Med. Chem.52, 5241–5252 (2009).
   PubMed Web of Science ®Google Scholar
• Laine DI, Xie H, Buffet N et al. Discovery of novel 8-azoniabicyclo[3.2.1]octane carbamates as muscarinic acetylcholine receptor antagonists. Bioorg. Med. Chem. Lett.17, 6066–6069 (2007).
   PubMed Web of Science ®Google Scholar
• Jin J, Wang Y, Shi D et al. Discovery of novel and long-acting muscarinic acetylcholine receptor antagonists. J. Med. Chem.51, 4866–4869 (2008).
   PubMed Web of Science ®Google Scholar
• Jin J, Budzik B, Wang Y, Shi D, Wang F, Xie H et al. Discovery of biphenyl piperazines as novel and long-acting muscarinic acetylcholine receptor antagonists. J. Med. Chem.51, 5915–5918 (2008).
   PubMed Web of Science ®Google Scholar
• Laine DI, McCleland B, Thomas S et al. Discovery of novel 1-azoniabicyclo[2.2.2]octane muscarinic acetylcholine receptor antagonists. J. Med. Chem.52(8), 2493–2505 (2009).
   PubMed Web of Science ®Google Scholar
• Zinner NR. Trospium chloride: a different anticholinergic. Expert Rev. Obstet. Gynecol.1(1), 29–39 (2006).
   Google Scholar
• Napier C, Gupta P. Darifenacin is selective for the human recombinant M3 receptor subtype. Neurourol. Urodyn.21, A445 (2002).
   Google Scholar
• Bauhofer A, Maus J, Petzold U, Szelenyi I. Synergistic effects of dexpirronium and formoterol in guinea pigs. J. Allergy Clin. Immunol.121(2), S8–S9 (2008).
   Google Scholar
• Patacchini R, Bergamaschi, Harrison S et al.In vitro pharmacological profile of CHF5407, a potent, long-acting and selective muscarinic M3 receptor antagonist. Presented at: Annual Congress European Respiratory Society. Stockholm, Sweden, 15–19 September 2007 (Abstract P316).
   Google Scholar
• Villetti G, Bassani F, Bergamaschi M et al.In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407. Presented at: Annual Congress European Respiratory Society. Stockholm, Sweden, 15–19 September 2007 (Abstract P318).
   Google Scholar
• Starck J-P, Provins L, Christophe B et al. Alkyne-quinuclidine derivatives as potent and selective muscarinic antagonists for the treatment of COPD.Bioorg. Med. Chem. Lett.18(8), 2675–2678 (2008).
   PubMed Web of Science ®Google Scholar